# Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma

> **NCT07657325** · — · RECRUITING · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 110 (estimated)

## Conditions studied

- Renal Cell Carcinoma (RCC)

## Interventions

- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT07657325
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2028-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07657325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07657325, "Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07657325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*